Home › Abdominal Aortic Aneurysm › NCT07473102
PET Imaging of MMP Activation in AAA: Clinical Component
RecruitingEarly phase 1Healthy volunteers welcome
Who can join
Ages 18 and older · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: Healthy Volunteers * No history of claustrophobia or other preventing condition that has previously or would interfere with completion of protocol-specified imaging sessions. * Able to comprehend and willing to follow instructions for the study procedures as called for by the protocol. * Capable of lying still and supine within the PET/CT scanner for \~1 hour and follow instructions for breathing protocol during the CT portion. * No illicit drug use or other inhaled drug use (including pharmacologic agents, recreational agents, or illicit drugs) within the past year. * No known history of cardiac, pulmonary, hepatic or renal disease or diabetes * BMI ≤ 40 Exclusion Criteria: Healthy Volunteers * Inability to receive and sign informed consent; * Pregnant (confirmed by urine pregnancy test) and/or breastfeeding * Patient with chronic renal disease whose glomerular filtration rate (GFR) is less than 30 mL/min/1.73 m2 * Patients with an unstable clinical condition that in the opinion of the principal investigators or designee precludes participation in the study. * Is deemed likely to be unable to perform all research procedures for any reason, (e.g., subjects unable to lie still or inability to tolerate up to 60 minutes in a supine position with arms up during the PET imaging procedures due to chronic back/shoulder pain or arthritis as assessed by physical examination and medical history). * Currently using recreational drugs. * Body weight of \>300 lbs. (weight limit of the PET table). * Currently enrolled in another study using an investigational drug or underwent a study the last year involving investigational use of radiotracers or CT would confound results or with a radiation exposure when combined with this study would be deemed as excessive by the Sponsor-Investigator. Inclusion Criteria: Patients with AAA electively or semi-electively scheduled for surgical repair * Men or women 40-80 years of age * Willing and able to provide informed consent * Medically managed hypertension and hyperlipidemia * No history of claustrophobia or other preventing condition that has previously or would interfere with completion of protocol-specified imaging sessions * Able to comprehend and willing to follow instructions for the study procedures as called for by the protocol * Patients with AAA indicated for surgical repair (5.0 \[female\] - 5.5cm \[male\]), incidentally identified large(r) AAAs (\>5.5 or 6.0 cm), and rapidly expanding AAAs (\> 0.5 cm in 6 months or \> 1 cm in 12 months) per Guidelines of the Society for Vascular Surgery. Exclusion Criteria: Patients with AAA electively or semi-electively scheduled for surgical repair * Inability to receive and sign informed consent. * Currently enrolled in another study using an investigational drug * Pregnant (confirmed by urine pregnancy test) and/or breastfeeding * Patient with chronic renal disease whose GFR is less than 30 mL/min/1.73 m2 * Documented allergy to iodinated contrast and/or shellfish * Patients with an unstable clinical condition that in the opinion of the principal investigators or designee precludes participation in the study. * Inability to tolerate 60 minutes in a supine position with arms down at sides, as necessary for PET/CT. * Other conditions such as symptomatic/recently treated coronary disease, cancer requiring oncologic management, or autoimmune/inflammatory diseases (e.g., rheumatoid arthritis or multiple sclerosis). * Non-AAA volunteers may not carry a diagnosis of aortoiliac occlusive disease, as documented by their treating vascular surgeon, as significantly progressed atherosclerotic disease may demonstrate exaggerated, associated MMP activity.
About the study
A first-in-human evaluation of \[64Cu\]-RYM2 with PET/CT will be performed to: a) assess its safety, biodistribution, and radiation dosimetry in normal volunteers (WU) and; b) in AAA patients undergoing surgery (WU and Yale), evaluate radiotracer pharmacodynamics and correlate PET imaging characteristics (WU) with ex vivo tissue measurements (Yale).
What is being tested
- Cu-64-RYM2 (drug)
- PET imaging using Cu-64 (drug)
Sponsor: Washington University School of Medicine · Participants: 28 · Started: Nov 3, 2025
Contact the study team
- Kitty Harrison, RN, BSN · Phone: 314-747-0183
- Robert Gropler, MD · Phone: 314-747-0183
Official record on ClinicalTrials.gov — NCT07473102
Locations in the U.S.
| Missouri | Washington University School of Medicine, St Louis |
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.